Skip to main content

Samsara BioCapital — Portfolio, Page 5

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$12.1B
Total invested
$113.4M
Avg. check
15
Industries
Biotechnology 24Health Care 18Medical 9Life Science 7Therapeutics 7Biopharma 7+9 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 97120 of 132
A2 Biotherapeutics
May 2025

A2 Biotherapeutics develops T cell therapies targeting solid tumors precisely.

Biotechnology · Agoura Hills$300K Grant
Surrozen
March 2025

Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.

Biotechnology · South San Francisco$175.0M Post Ipo Equity
Ottimo Pharma
December 2024

Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.

Biotechnology · Sandwich$140.0M Series A
Enara Bio
October 2024

Ervaxx is illuminating the immune interface to develop new cancer therapies.

Biotechnology · London$32.5M Series B
ImmunOs Therapeutics
September 2024

ImmunOs Therapeutics is a clinical-stage biotechnology company.

Biotechnology · Schlieren$11.0M Series C
Nura Bio
September 2024

Nura Bio is a clinical-stage biopharmaceutical company focused on developing neuroprotective therapies to treat neurological diseases.

Biotechnology · South San Francisco$68.0M Series A
Seismic Therapeutic
September 2024

Seismic Therapeutic is a biotechnology company developing machine-learning technology for immunology drug development.

Biotechnology · Watertown$25.0M Series B
OrsoBio
September 2024

OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders.

Biopharma · Palo Alto$67.0M Series B
Pathalys Pharma
August 2024

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.

Biopharma · Raleigh$105.0M Series B
Autobahn Therapeutics
July 2024

Clinical stage biotechnology company developing restorative treatments for people affected by neuropsychiatric & neuroimmunologic disorders

Biotechnology · San Diego$100.0M Series C
Fluent BioSciences
March 2024

Fluent Biosciences, a life science company, offering a molecular analysis of cells without the use of complex microfluidic instrumentation.

Biotechnology · WatertownGrant
Attralus
February 2024

Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.

Biopharma · San Francisco$56.0M Series B
SpringWorks Therapeutics
December 2023

SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.

Biopharma · Stamford$275.0M Post Ipo Equity
Arcellx
November 2023

Arcellx develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases.

Biopharma · Redwood City$200.0M Post Ipo Equity
Eyebiotech
November 2023

Eyebiotech is an ophthalmology biotechnology company that specializes in therapies for eye diseases.

Biotechnology · New York$65.0M Series A
Alpine Immune Sciences
November 2023

Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.

Biotechnology · Seattle$150.0M Post Ipo Equity
Tentarix Biotherapeutics
September 2023

Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology.

Biotechnology · San Diego$35.0M Series B
Septerna
July 2023

Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases.

Biotechnology · San Francisco$150.0M Series B
Upstream Bio
June 2023

Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.

Biotechnology · Waltham$200.0M Series B
Elevation Oncology
June 2023

Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.

Biopharma · New York$50.0M Post Ipo Equity
ACELYRIN
September 2022

ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.

Biopharma · Los Angeles$300.0M Series C
MiroBio
June 2022

MiroBio is Harnessing the natural control mechanisms of the immune system.

Biotechnology · Oxford$97.0M Series B
Chinook Therapeutics
May 2022

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science.

Biotechnology · Vancouver$105.0M Post Ipo Equity
Ionpath
May 2022

Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies.

Biotechnology · Menlo ParkCorporate Round

Where Samsara BioCapital invests

Biotechnology24
Health Care18
Medical9
Life Science7
Therapeutics7
Biopharma7

About Samsara BioCapital's portfolio

How many companies has Samsara BioCapital invested in?

Samsara BioCapital has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Samsara BioCapital invest in?

Samsara BioCapital's top investment sectors include Biotechnology, Health Care, Medical, Life Science, Therapeutics. The firm invests across 15 different industry categories.

What is Samsara BioCapital's largest investment?

Among tracked funding rounds, ACELYRIN received $300.0M in a Series C round. Samsara BioCapital's total known invested capital is $12.1B.

What is the average investment size for Samsara BioCapital?

Samsara BioCapital's average investment size is $113.4M across its portfolio of 132 companies.

What are Samsara BioCapital's most recent investments?

Recent Samsara BioCapital portfolio additions include A2 Biotherapeutics, Surrozen, Ottimo Pharma, Enara Bio, ImmunOs Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →